Ionis Pharmaceuticals (IONS) – Business Wire
-
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for Familial Chylomicronaemia Syndrome, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in Scotland
-
Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes
-
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
-
Antisense Therapeutics Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website
-
Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints
-
Antisense Therapeutics Announces Appointment of US-based Consultant Medical Director
Back to IONS Stock Lookup
